Investment Analysts’ Recent Ratings Changes for Intellia Therapeutics (NTLA)

Several analysts have recently updated their ratings and price targets for Intellia Therapeutics (NASDAQ: NTLA):

• 9/9/2026 – Intellia Therapeutics had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $30.00 price target on the stock.
• 9/9/2026 – Intellia Therapeutics had its price target raised by Wedbush from $12.00 to $13.00. They now have a “neutral” rating on the stock.
• 9/9/2026 – Intellia Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $25.00 price target on the stock.
• 8/25/2026 – Intellia Therapeutics had its “market outperform” rating reaffirmed by Citigroup Inc..
• 8/25/2026 – Intellia Therapeutics had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $30.00 price target on the stock.
• 8/8/2026 – Intellia Therapeutics was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 8/7/2026 – Intellia Therapeutics was upgraded by Evercore Inc from “hold” to “outperform”. They now have a $24.00 price target on the stock.
• 7/17/2026 – Intellia Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling at Intellia Therapeutics

In related news, CAO Michael Dube sold 2,641 shares of the stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $16.78, for a total transaction of $44,315.98. Following the sale, the chief accounting officer directly owned 66,886 shares of the company’s stock, valued at approximately $1,122,347.08. This represents a 3.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP J III sold 4,677 shares of the company’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $18.00, for a total transaction of $84,186.00. Following the completion of the transaction, the executive vice president owned 156,286 shares of the company’s stock, valued at approximately $2,813,148. This trade represents a 2.91% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 3.50% of the company’s stock.

Intellia Therapeutics, Inc is a biotechnology company focused on developing curative treatments using CRISPR-based gene-editing technology. The company’s approach is designed to make targeted changes to disease-associated genes, including through in vivo therapies that edit genes directly inside the body.

Intellia’s pipeline includes NTLA-2001, an investigational treatment designed to address transthyretin amyloidosis by editing the TTR gene, and NTLA-2002, an investigational therapy targeting hereditary angioedema through editing of the KLKB1 gene.